Life Sciences

Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.

 

Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.

 

We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by forming the right alliances, better allocating resources and building trust with customers.

Our Latest thinking

The Unstoppables: Success stories of the world’s most inspiring entrepreneurs

The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.

12 Nov 2024 Stasia Mitchell

Life sciences dealmaking in a time of change

Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.

08 Jan 2024 Subin Baral

Global Voices in Health Care

The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.

16 Oct 2023 Aloha McBride

Supply chain visibility strategic priority for pharma

With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.

04 Oct 2023 Derron Stark +1

How digital is changing the tax strategy for MedTech

As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.

18 Aug 2023 Ana Maria Romero +2

Case study: Takeda’s finance transformation with EY teams

In this case study, learn how leading pharmaceutical company Takeda is creating value for patients through finance innovation and process excellence.

14 Aug 2023 Frederik Schmachtenberg +2

How Takeda harnessed the power of the metaverse for positive human impact

Learn how Takeda harnessed the power of the metaverse for positive human impact.

27 Jun 2023 Edwina Fitzmaurice +4

Innovation can utilize data for value-based care

Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.

20 Mar 2023 Pamela Spence

Life sciences businesses transform tax and finance

Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.

07 Mar 2023 EY Global

Why life sciences tax departments need to act now on sustainability

Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.

11 Jan 2023 Rick Fonte +2

How innovative infostructure can power the purpose of integrated care systems

Sharing organized and complete data to generate insights for better health outcomes is the driving force behind joined-up care in integrated care systems (ICSs).

18 Sep 2022 Aloha McBride +1

CDMOs are becoming emerging technology leaders

Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.

14 Jul 2022 Dr. Isabelle Heiber

Takeda’s journey through digitalization

Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.

01 Jul 2022 Helmut Rattenberger +1

How to navigate EU regulations for drug-device combination products

The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.

10 Mar 2022 EY Global

How one entrepreneur seeks to make affordable health care a reality

Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.

01 Mar 2022 EY Global

Are digital twins key to more personal, equitable and efficient care?

Digital patient twins tap into the transformative value data beyond the traditional medical to provide health providers and payers actionable insights. Learn more at ey.com/smarthealth.

25 Feb 2022 Aloha McBride

How ecosystem participation drives more value for life sciences deals

Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.

10 Jan 2022 Subin Baral

Health sciences wellness experience

Join EY panellists and guests, as they expand the traditional definitions of innovation to meet ever-growing needs and expectations.

08 Dec 2021

Genome editing technologies create buzz in medicine

Technologies that allow genomic alteration are gaining in popularity, but they’ll need to overcome key hurdles to become mainstream. Learn more.

05 Oct 2021 Dr. Isabelle Heiber +1

How to account for outcome-based payment arrangements in life sciences

The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.

23 Sep 2021 EY Global

    Life Sciences 4.0

    When the human body is the biggest data platform, who will capture value?



    Contact us
    Like what you’ve seen? Get in touch to learn more.
    You are visiting EY mena (en)
    mena en